pyrazolanthrone has been researched along with Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Gehringer, M; Koch, P; Laufer, SA | 1 |
| Bu, F; Ouyang, L; Pan, X; Pei, J; Shuai, W; Wang, A; Wang, G; Wu, Y; Zhao, M; Zhu, Y | 1 |
| Cho, Y; Jeon, SD; Kim, C; Kim, KY; Kim, MG; Lee, HS; Yoon, J; Yoon, MJ | 1 |
| Kim, J; Kim, KS; Lee, HM | 1 |
| Liu, Y; Tan, WF; Wang, J; Yang, J; Zhang, X | 1 |
| Cao, Q; Chen, GL; Fang, WH; Jiang, XR; Li, HH; Li, M; Li, Y; Liu, X; Ping, GF; Wang, LH; Wang, S; Wu, CF; Yang, JY | 1 |
| Fang, B; Guo, W; Liu, J; Lu, Y; Wang, L; Wei, X; Wu, S; Xu, B | 1 |
| Fu, K; Li, B; Mu, C; Ren, H; Wang, D; Wang, G | 1 |
| Jeon, HW; Kim, WH; Lee, KJ; Lee, SH; Lee, YM | 1 |
| Davies, C; Tournier, C | 1 |
| Antoccia, A; Berardinelli, F; Castedo, M; Galluzzi, L; Harper, F; Jemaà, M; Kepp, O; Kroemer, G; Lissa, D; Malik, SA; Mariño, G; Pierron, G; Rello-Varona, S; Schlemmer, F; Senovilla, L; Tailler, M; Vitale, I | 1 |
| Bilter, GK; Boluro-Ajayi, M; Ennis, BW; Fultz, KE; Smith, KA; Stein, B; Westwick, JK; Zhu, D | 1 |
| Bach, LA; Fu, P; Thompson, JA | 1 |
| Jang, YS; Kim, BS; Kook, SH; Lee, HJ; Lee, JC; Lee, KY; Lee, SA; Son, YO | 1 |
| Derijard, B; Giorgelli, JL; Martial, S; Renaudo, A; Soriani, O | 1 |
2 review(s) available for pyrazolanthrone and Neoplasms
| Article | Year |
|---|---|
Inhibitors of c-Jun N-terminal kinases: an update.
Topics: Central Nervous System Diseases; Humans; Inflammation; Isoenzymes; JNK Mitogen-Activated Protein Kinases; Models, Molecular; Molecular Structure; Neoplasms; Protein Binding; Protein Kinase Inhibitors | 2015 |
Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies.
Topics: Animals; Anthracenes; Apoptosis; Brain; Enzyme Activation; Humans; Isoenzymes; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasms; Neurodegenerative Diseases | 2012 |
14 other study(ies) available for pyrazolanthrone and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
Topics: Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasms; Phosphorylation; Protein Isoforms | 2022 |
A JUN N-terminal kinase inhibitor induces ectodomain shedding of the cancer-associated membrane protease Prss14/epithin via protein kinase CβII.
Topics: Anthracenes; Cell Line, Tumor; Humans; MAP Kinase Kinase 4; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Transport; Serine Endopeptidases; Signal Transduction; Tetradecanoylphorbol Acetate | 2020 |
A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta.
Topics: Anthracenes; Cell Line; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Killer Cells, Natural; Lymphocyte Activation; MAP Kinase Kinase 1; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myb; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Signal Transduction; Syk Kinase; Transcription Factor AP-1; Transforming Growth Factor beta; Tumor Escape | 2014 |
JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.
Topics: Anthracenes; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; K562 Cells; KB Cells; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Neoplasms; Neoplastic Stem Cells; RNA Interference; RNA, Small Interfering | 2015 |
SL4, a chalcone-based compound, induces apoptosis in human cancer cells by activation of the ROS/MAPK signalling pathway.
Topics: Animals; Anthracenes; Apoptosis; bcl-X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Chalcone; Chalcones; Enzyme Activation; Female; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1; Imidazoles; Inhibitor of Apoptosis Proteins; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Pyridines; Reactive Oxygen Species; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2015 |
Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Molecular Structure; Neoplasms; Phosphorylation | 2009 |
DJ-1, a cancer and Parkinson's disease associated protein, regulates autophagy through JNK pathway in cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Anthracenes; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Neoplasms; Oncogene Proteins; Protein Deglycase DJ-1; Protein Kinase Inhibitors; RNA Interference; Sequestosome-1 Protein; Signal Transduction; Transfection | 2010 |
Attenuated expression and function of the RECK tumor suppressor under hypoxic conditions is mediated by the MAPK signaling pathways.
Topics: Anthracenes; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Flavonoids; GPI-Linked Proteins; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Mitogen-Activated Protein Kinases; Neoplasms; Promoter Regions, Genetic; Protein Binding; Pyridines; Response Elements; RNA, Messenger; Signal Transduction | 2011 |
Selective killing of p53-deficient cancer cells by SP600125.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Microscopy, Video; Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Endothelial Cells; Female; Flow Cytometry; G2 Phase; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms | 2005 |
Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6.
Topics: Anthracenes; Cell Movement; Humans; Imidazoles; Insulin-Like Growth Factor Binding Protein 6; Insulin-Like Growth Factor I; Ligands; MAP Kinase Signaling System; Mutation; Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Structure, Tertiary; Pyridines; Rhabdomyosarcoma; Tumor Cells, Cultured | 2007 |
Inhibition of c-Jun N-terminal kinase sensitizes tumor cells to flavonoid-induced apoptosis through down-regulation of JunD.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA; Flavonoids; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred BALB C; Neoplasms; Phosphorylation; Plant Extracts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-jun; Rhus; RNA, Small Interfering; Transcription Factor AP-1; Transfection | 2008 |
SP600125 inhibits Kv channels through a JNK-independent pathway in cancer cells.
Topics: Anthracenes; Cell Line, Tumor; Cinnamates; Cyclopropanes; Extracellular Signal-Regulated MAP Kinases; Humans; Ion Channel Gating; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Neoplasms; p38 Mitogen-Activated Protein Kinases; Potassium Channels, Voltage-Gated | 2008 |